SCHEMBL13649017

SCHEMBL13649017

O=C(CNc1nc(Cl)ncc1Br)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
AGTR1 P30556 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
MAPT P10636 3/20 0.42
GAA P10253 2/20 0.42
RAB9A P51151 3/20 0.41
KDM4E B2RXH2 2/20 0.41
AKR1C3 P42330 1/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
GSK3B P49841 3/20 0.40
HPGD P15428 3/20 0.39
NPC1 O15118 2/20 0.39
MAPK1 P28482 2/20 0.39
CYP3A4 P08684 2/20 0.39
ALOX15 P16050 1/20 0.39
CES1 P23141 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTT P42858 1/20 0.38
CDK1 P06493 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1115794 0.81 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2MAPTRAB9AMEN1
SCHEMBL6212214 0.76 PDE5A (0.55) ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E
SCHEMBL13649018 0.75 KMT2A (0.41) ALDH1A1SMN1; SMN2MAPTRAB9AMEN1
SCHEMBL27635199 0.74 SIRT5 (0.46) ALDH1A1KDM4EMEN1KMT2ASIRT5
SCHEMBL4064328 0.74 CA2 (0.62) GSK3BCDK1CDK2CCNB1CCNE1
SCHEMBL17595892 0.73 STK17A (0.41) ALDH1A1MAPTMEN1KMT2AMAPK1
SCHEMBL16570401 0.73 MEN1 (0.44) ALDH1A1MEN1KMT2ACDK1CDK2
SCHEMBL6212947 0.71 APP (0.48) MAPTHPGDCYP3A4SIRT5CYP1A2
SCHEMBL3448628 0.71 PIK3CD (0.47) ALDH1A1RAB9AMEN1KMT2ANPC1
SCHEMBL13655334 0.71 MEN1 (0.38) ALDH1A1MEN1KMT2ACYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598260-B2 CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-10-06 US disclosed
US-7598260-B2 CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-10-06 US disclosed
US-20080039447-A1 CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents BRUMBY THOMAS 2008-02-14 US disclosed
US-20080039447-A1 CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents BRUMBY THOMAS 2008-02-14 US disclosed
US-7291624-B2 CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2007-11-06 US disclosed
US-7291624-B2 CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2007-11-06 US disclosed
US-7235561-B2 Compound and a composition including such a compound SCHERING AG (DE) 2007-06-26 US disclosed
US-7235561-B2 Compound and a composition including such a compound SCHERING AG (DE) 2007-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039447-A1 CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents CDK2, CDK1, CDK6 ALDH1A1 2190/4885AGTR1 1382/4885SMN1; SMN2 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.